Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

H. influenzae infections not tied to worse outcomes for CF adults

Infection with an airway bacterium called Haemophilus influenzae isn’t linked with worse lung health outcomes among adults with cystic fibrosis (CF), a study suggests. “Our study is the first to specifically dissect the natural history and consequences of H. influenzae infection in adult [people with] CF,” the researchers wrote. The…

Trikafta may ease inflammation, tissue damage in patients’ lungs

The cystic fibrosis (CF) treatment Trikafta leads to changes in airway cell gene expression, or activity, that may help fend off bacterial infections and lessen lung damage, researchers report. “This study identifies mechanisms through which ETI [Trikafta] is likely to improve antibacterial function, reduce lung damage, and reduce…

Trikafta triggers diabetes remission in 4 CF patients: Report

Treatment with Trikafta triggered diabetes remission in four people with cystic fibrosis (CF) at a center in Australia, with each of these patients experiencing complete resolution of CF-related diabetes, or CFRD, after starting on the approved triple therapy. In all four cases, the patients were able to stop…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.